About Celularity
Celularity is a company based in Warren (United States) founded in 2016.. Celularity has raised $290 million across 8 funding rounds from investors including United Therapeutics, Human Longevity and Sorrento Therapeutics. The company has 123 employees as of December 31, 2024. Celularity has completed 1 acquisition, including CariCord. Celularity offers products and services including NK Cell Platform, T Cell Platform, Exosomes, and Advanced Biomaterials. Celularity operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Warren, United States
- Employees 123 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Celularity Inc.
-
Annual Revenue
$54.22 M138.11as on Dec 31, 2024
-
Net Profit
$-57.89 M70.51as on Dec 31, 2024
-
EBITDA
$-30.63 M54.39as on Dec 31, 2024
-
Total Equity Funding
$290 M (USD)
in 8 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Dec 22, 2025
-
Investors
United Therapeutics
& 6 more
-
Employee Count
123
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Celularity
Celularity is a publicly listed company on the NASDAQ with ticker symbol CELU in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Celularity
Celularity offers a comprehensive portfolio of products and services, including NK Cell Platform, T Cell Platform, Exosomes, and Advanced Biomaterials. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing NK cell therapies against cancer and disorders.
Platform for engineered T cell therapies targeting immune diseases.
Advanced biomaterials derived from placenta for therapeutic applications.
Products for tissue repair and disease treatment using placental sources.
Unlock access to complete
Unlock access to complete
Funding Insights of Celularity
Celularity has successfully raised a total of $290M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(15 Aug 2017)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2025 | Amount | Post-IPO - Celularity | Valuation |
investors |
|
| Oct, 2025 | Amount | Post-IPO - Celularity | Valuation |
investors |
|
| Jul, 2025 | Amount | Post-IPO - Celularity | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Celularity
Celularity has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include United Therapeutics, Human Longevity and Sorrento Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in innovative technology startups.
|
Founded Year | Domain | Location | |
|
Multi-stage tech and life sciences focused venture capital firm investing primarily in the US
|
Founded Year | Domain | Location | |
|
Treatments for chronic and life-threatening diseases are developed and commercialized.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Celularity
Celularity has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CariCord. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cord blood and tissue are processed for long-term storage.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Celularity
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Celularity Comparisons
Competitors of Celularity
Celularity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Celularity
Frequently Asked Questions about Celularity
When was Celularity founded?
Celularity was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Celularity located?
Celularity is headquartered in Warren, United States. It is registered at Warren, Michigan, United States.
Who is the current CEO of Celularity?
Robert Hariri is the current CEO of Celularity.
Is Celularity a funded company?
Celularity is a funded company, having raised a total of $290M across 8 funding rounds to date. The company's 1st funding round was a Post-IPO of $2M, raised on Aug 15, 2017.
How many employees does Celularity have?
As of Dec 31, 2024, the latest employee count at Celularity is 123.
What is the annual revenue of Celularity?
Annual revenue of Celularity is $54.22M as on Dec 31, 2024.
What does Celularity do?
Celularity was founded in 2016 and is headquartered in Warren, United States. Allogeneic cell therapies are developed by the company, utilizing placenta-derived cells to address cancer, infectious diseases, and degenerative conditions. Operations center on product candidates such as CYNK-001, which targets acute myeloid leukemia and glioblastoma. The biotechnology sector focus includes clinical-stage advancements in regenerative medicine.
Who are the top competitors of Celularity?
Celularity's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Celularity offer?
Celularity offers NK Cell Platform, T Cell Platform, Exosomes, and Advanced Biomaterials.
Is Celularity publicly traded?
Yes, Celularity is publicly traded on NASDAQ under the ticker symbol CELU.
How many acquisitions has Celularity made?
Celularity has made 1 acquisition, including CariCord.
Who are Celularity's investors?
Celularity has 7 investors. Key investors include United Therapeutics, Human Longevity, Sorrento Therapeutics, Genting Group, and Celgene.
What is Celularity's ticker symbol?
The ticker symbol of Celularity is CELU on NASDAQ.